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Abstract
Background: The decision-making process for stroke prevention in atrial fibrillation (AF) requires  
a comprehensive assessment of risk vs. benefit and an appropriate selection of antithrombotic agents 
(e.g., warfarin, non-vitamin K antagonist oral anticoagulants [NOACs]). The aim of this pilot-test was 
to examine the impact of a customised decision  support tool — the Computerised Antithrombotic Risk 
Assessment Tool (CARATV2.0) using antithrombotic therapy on a cohort of patients with AF.
Methods: In this prospective interventional study, 251 patients with AF aged ≥ 65 years, admitted to 
a teaching hospital in Australia were recruited. CARATV2.0 generated treatment recommendations 
based on patient medical information. Recommendations were provided to prescribers for consideration.
Results: At baseline (admission), 30.3% of patients were prescribed warfarin, 26.7% an antiplatelet, 
8.4% apixaban, 8.0% rivaroxaban, 3.6% dabigatran. CARATV2.0 recommended a change of therapy 
for 153 (61.0%) patients. Through recommendations of CARATV2.0, at discharge, 40.2% of patients 
were prescribed warfarin, 17.7% antiplatelet, 14.3% apixaban, 10.4% rivaroxaban, 5.6% dabigatran. 
Overall, the proportion of patients receiving an antithrombotic on discharge increased significantly 
from baseline (admission) (baseline 77.2% vs. 89.2%; p  < 0.001). Prescribers moderately agreed with  
CARATV2.0’s recommendations (kappa = 0.275, p < 0.001). Practical medication safety issues were cited  
as major reasons for not accepting a desire to continue therapy with CARATV2.0’s recommendations. 
Factors predicting the prescription of antiplatelets rather than anticoagulants included higher bleeding 
risk and high risk of falls. An inter-speciality difference in therapy selection was detected. 
Conclusions: This decision support tool can help optimise the use of antithrombotic therapy in patients 
with AF by considering risk versus benefit profiles and rationalising treatment selection. (Cardiol J 
2017; 24, 2: 176–187)
Key words: decision-making, computer-assisted, anticoagulant agents, warfarin,  
atrial fibrillation, stroke, clinical decision support
Introduction
The decision-making process in antithrom-
botic therapy for stroke prevention in atrial fibril-
lation (AF) is complicated by therapy options and 
considerations of risk versus benefit assessment. 
Three non-vitamin K antagonist oral anticoagu-
lants (NOACs) — dabigatran, rivaroxaban and 
apixaban — have been developed and approved to 
overcome the limitations of warfarin, but they are 
not without risk and have different pharmacological 
profiles [1, 2]. Compared with warfarin, the NOACs 
do not require routine monitoring of coagulation 
parameters and have fewer interactions with other 
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drugs and foods, which enhances the convenience 
of therapy management. However, in contrast to 
warfarin, most NOACs need dosage adjustment in 
patients with renal impairment and are contraindi-
cated in severe liver impairment. For patients with 
gastrointestinal disease, some NOACs (such as 
dabigatran) are not tolerated as well as with war-
farin treatment. More frequent dosing is needed 
for some NOACs (e.g., twice daily for dabigatran 
and apixaban) compared to warfarin (once daily), 
which may reduce patients’ adherence, especially 
in older patients who were using polypharmacy [1]. 
Additionally, they are more expensive, which un-
derpins recent recommendations to prioritise the 
use of warfarin for those patients with whom it is 
appropriate [3]. Regarding the risk versus benefit 
assessment of using antithrombotics, currently 
both international (the ESC and AHA/ACC/HR 
guidelines) and Australian guidelines (the Thera-
peutic and NPS guidelines) recommend considera-
tion of both the risk of bleeding and anticoagulation 
control (INR, time in therapeutic range) in addition 
to the risk of stroke [4–7]. Therefore, health pro-
fessionals could improve care with a more tailored 
evaluation by having a complete assessment of 
patients with AF for both initiation of therapy and 
follow-up [8, 9]. 
To assist clinicians in selecting appropriate 
antithrombotic therapy for patients with AF, the 
Computerised Antithrombotic Risk Assessment 
Tool (CARAT) was previously developed and suc-
cessfully trialled [10]. This decision support tool 
facilitates a comprehensive review of risk factors 
and calculates the estimated risk versus benefit of 
therapy for individual patients, taking into account 
any relevant medication safety issues (e.g. renal 
function, fall risk). In view of the recent availability 
of NOACs and further evidence from clinical trials 
[3, 6, 11], the tool has been updated (CARATV2.0) 
[12], in-line with current guidelines (e.g. the Aus-
tralian Therapeutic Guidelines [4], NPS Medicine-
Wise guidelines [13], AHA/ACC/HR guideline [6], 
American Chest Physician Guidelines [14], and 
the ESC Guidelines [7]), including the broader 
literature [1, 3, 15, 16]. 
As a pre-test of its underpinning algorithm and 
data inputs, CARATV2.0 was piloted in a cohort of 
patients admitted to a Sydney hospital for manage-
ment of their AF. The main aim of this study was 
to evaluate the potential impact of CARATV2.0 on 
the use of antithrombotic therapy and to ensure 
that CARATV2.0 included all of the appropriate 
inputs for decision-making around antithrombotics 
from the clinicians’ perspective, before evaluating 
it in a randomized controlled trial. Specifically, 
CARATV2.0’s inputs were confirmed by seeking 
clinicians’ opinions on the reasons for agreeing or 
disagreeing with the tool’s assessment of patients 
and its recommendations for antithrombotic thera-
py. The proportion of patients receiving antithrom-
botic therapy at admission versus at discharge 
(pre vs. post application of the decision support 
tool) was compared to evaluate the impact of this 
tool. Factors associated with treatment selection 
at discharge were also identified. 
Methods
Design and setting
This prospective cohort study was conducted 
in a tertiary teaching hospital in Sydney, Australia, 
from August 2015 until October 2015. CARATV2.0 
was used to review patients with AF admitted to 
the hospital and to generate recommendations for 
antithrombotic therapy. 
Ethics approval for the study was obtained 
from the respective institution of human research 
and ethics committees (REF NO. HREC/15/ 
/HAWKE/103).
Participant recruitment
Both patients and prescribers were recruited 
as participants. Prescribers were recruited through 
initial contact at seminars and at clinical meetings 
in the target wards where patients with AF were 
likely to be admitted (i.e. cardiology, neurology, 
aged care and general medicine). Subsequently, 
prescribers were approached directly to obtain 
their informed written consent to participate. 
Patients with AF were identified by the princi-
pal researcher (a medical doctor) through screening 
of admissions to the hospital wards. Patients were 
selected if they satisfied the following criteria: 
aged 65 years or older; could speak English; had 
a principal diagnosis of non-valvular AF or a second- 
ary diagnosis of AF regarded as contributory to 
the admission; and were able to (or had a person 
responsible who was able to) provide informed 
written consent to participate in the study. Patients 
were recruited through face-to-face contact by the 
principal researcher on the wards.
Data collection (trial scenario)
The researcher visited target wards daily and 
liaised with the ward staff to identify patients with 
AF. The medical records of each eligible consenting 
patient were then reviewed to extract relevant data 
such as medical history. Where key data needed 
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specific clarification, the relevant health profes-
sionals, the patients, or both, were approached 
directly. 
The extracted data were used by the re-
searcher to populate CARATV2.0 in order to 
generate a treatment recommendation for each 
patient. CARATV2.0’s recommendations were 
then presented to the prescribers as follows: 
documented clinical notes, discussed during ward 
rounds, or discussed via phone after paging the 
doctor. Prescriber agreement or disagreement with 
CARATV2.0’s recommendations, and the reasons 
for alternative treatment selection, were recorded. 
Each patient’s management was followed prior to 
hospital discharge.
Algorithm of CARATV2.0 
CARATV2.0 (currently an Excel prototype) is 
an electronic tool that canvases a range of factors 
to determine a patient’s risk of stroke versus risk 
of bleeding. Stroke risk was assessed with CHADS2 
[17] and CHA2DS2VASc [18]; bleeding risk was 
assessed with HAS-BLED [19] and HEMORR2- 
HAGES [20]. The two sets of scores verify each 
assessment, giving weight to the highest score 
(level of risk). The four scores are each categorized 
into low, intermediate or high risk. CARATV2.0 
additionally considers major medication safety is-
sues that may affect treatment choice (e.g. renal 
and liver function, drug interactions, fall risk and 
cognitive function) [10]. 
When applying CARATV2.0, a patient is 
considered eligible for oral anticoagulants when 
the risk of stroke (assessed by CHADS2 [17] or 
CHA2DS2VASc [18]) is equal to or higher than the 
risk of bleeding (assessed by HAS-BLED [19] or 
HEMORR2HAGES [20]). When the bleeding risk of 
using oral anticoagulants in the patient outweighs 
the benefit of stroke prevention, CARATV2.0 
considers the patient unsuitable for oral anticoagu-
lants; alternative treatment (e.g. an oral antiplate-
let) and specialist consultation are recommended 
instead. Given that CARATV2.0 was developed pri-
marily for an Australian setting, its treatment rec-
ommendations followed the Australian Therapeutic 
Guidelines [4] and were aligned with the Australian 
Government Review [3]. Whenever the patient was 
deemed to be eligible for oral anticoagulants, either 
warfarin or NOACs, and had no contraindications 
to warfarin or NOACs, CARATV2.0 considered 
warfarin as the first-line therapy and NOACs as 
an alternative therapy. However, it should be 
noted that the Australian guidelines differ slightly 
from international guidelines (ESC [2012] and the 
EHRA [2015]) in that the international guidelines 
advocate the use of NOACs over warfarin [7, 21]. 
The primary function of CARATV2.0 is to 
assess the need for antithrombotic therapy in 
patients who have AF as the primary indication. 
It does not make specific recommendations about 
combination therapies in the presence of multiple 
indications (an anticoagulant plus an antiplatelet), 
given the lack of evidence about the safety of using 
multiple agents. The tool does however, screen 
for other indications, such as ischemic heart 
disease (with or without stent) and valvular AF, 
which may also require antithrombotics and which 
may lead to the need for combination therapy, 
as identified by the American Chest Physician 
Guidelines [14]. Thereby, CARATV2.0 brings to 
the attention of prescribers that their patients 
may have other indications requiring additional 
antithrombotic therapy that may need to be care-
fully managed. CARATV2.0 does not make any 
recommendations about deprescribing any an-
tithrombotic therapy that a patient may be taking 
for other indications. 
Post hoc analysis
Post hoc analysis of CARATV2.0’s recommen-
dations was conducted after data collection was 
completed. This analysis assumed that CARATV2.0 
considered NOACs as the first-line therapy and 
warfarin as the second-line therapy (i.e. reversal 
of first- versus second-line therapies, in line with 
international guidelines [6, 7]). The patient data 
collected in the pilot study (trial scenario) were ap-
plied to CARATV2.0 to generate treatment recom-
mendations. Finally, the therapy recommended by 
CARATV2.0 (NOACs as first-line) was compared 
with the therapy received by patients in the trial 
scenario upon discharge. The purpose of this post 
hoc analysis was to demonstrate the adaptability of 
CARATV2.0 to the international guidelines and to 
review the recommendations when international 
guidelines were adopted.
Data analysis
Computerized data analysis employed SPSS 
(Statistical Package for the Social Sciences) Ver-
sion 19. T-tests, ANOVA, and Mann-Whitney 
U and Kruskal-Wallis tests were used to ex-
plore continuous variables. The c2 test examined 
differences in independent proportions. Kappa 
analysis assessed the level of agreement between 
CARATV2.0’s recommendations and the antithrom-
botic therapy actually prescribed at discharge. Lo-
gistic regression analysis identified predictors for 
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the use of antithrombotic therapy. All the relevant 
patient data (all variables listed in Table 1 and 
Table 2), including age, gender, admission depart-
ment, risk of stroke (assessed by CHADS2 [17] or 
CHA2DS2VASc [18]), risk of bleeding (assessed 
by HAS-BLED [19] or HEMORR2HAGES [20]), 
medical conditions (e.g., renal impairment, liver 
impairment. gastrointestinal bleeding, intracranial 
bleeding [ICH]), medication safety issues (e.g., 
adherence, cognition, fall risk), the number of 
medications were included in the univariate analy-
sis. All variables showing a significant association 
in the univariate analysis were then considered 
in the multivariate logistic regression modeling 
(Forward Wald). Although age and gender were 
not significant in the univariate analysis, they were 
also further explored in the multivariate analysis. 
The significance level for all analyses, univariate 
and multivariate, was set at p < 0.05.
Results
Patient characteristics 
Of the 253 patients recruited to the study, 
2 were excluded from analysis due to incomplete 
data (death during hospitalization). The average 
age of the 251 patients (51.0% females) was 82.3 ± 
± 8.2 years (Table 1). 
Baseline therapy at admission  
(pre-CARATV2.0)
At admission, 194 (77.2%) patients were using 
antithrombotics: 126 (50.5%) were using anticoagu-
lants and 67 (26.7%) were using antiplatelets (Fig. 1). 
Warfarin (± antiplatelet) was most commonly used 
76 (30.3%), followed by aspirin (± other antiplate-
let; 54, 21.5%), clopidogrel (13, 5.2%), apixaban 
(21, 8.4%), rivaroxaban (± antiplatelet; 20, 8.0%), 
dabigatran (9, 3.6%). Among the 57 patients on no 
antithrombotic therapy, 56 (98.2%) were catego-
rized as high stroke risk by CHA2DS2VASc, and 
37 (64.9%) as high risk by CHADS2).
CARATV2.0’s  recommendations 
Overall, CARATV2.0 recommended a change 
of therapy in 146 (58.2%) patients (Table 2). Among 
the 124 patients who were receiving an oral antico-
agulant at admission, only 102 (82.3%) patients were 
assessed as eligible for therapy by CARATV2.0. 
Among the 76 patients who were taking war-
farin on admission, 8 (9.5%) were specifically 
recommended an alternative therapy. Among the 
50 patients who were taking one of the NOACs 
on admission, 32 (64.0%) were specifically recom-
mended an alternative therapy by CARATV2.0.
Af ter  the review of  treatment using 
CARATV2.0, 167 (66.5%) patients were recom-
mended warfarin; 21 (8.0%) any NOAC (dabi-
gatran, rivaroxaban or apixaban); 12 (4.8%) either 
rivaroxaban or apixaban; 20 (8.0%) apixaban only; 
2 (0.8%) either dabigatran or rivaroxaban; and 
1 (0.4%) either dabigatran or apixaban. Twenty-
-eight (11.3%) patients were identified as unsuit-
able for any oral anticoagulant. 
Discharge therapy (post-CARATV2.0)
At discharge, the proportion of patients receiv-
ing antithrombotics (Table 2) significantly increased 
to 89.2% (from 77.2% at baseline; p < 0.001) 
(Fig. 1). More than 40% of patients were prescribed 
warfarin, while more than one-third were pre-
scribed one of the NOACs. Among the 146 (58.2%) 
patients who were recommended therapy changes 
by CARATV2.0, 36 (24.7%) were adopted by the 
prescribers before discharge. 
Among the factors affecting the selection of 
antithrombotics (at discharge), fall risk, bleeding 
risk, chronic kidney disease and being admitted to 
the neurology department had the greatest impact. 
Patients with a high risk of falls or a high risk of 
bleeding were more likely to receive antiplatelets 
than anticoagulants. Notably, patients with chronic 
kidney disease and those admitted to the neurology 
department were more likely to receive NOACs than 
warfarin (Supplemental Table 1 — see journal 
website).
Prescribers’ reasons for disagreement  
with CARATV2.0’s recommendations
Prescribers agreed with CARATV2.0’s rec-
ommendations on whether a patient was eligible 
for anticoagulants in 199 (79.3%) patients, and 
agreed with the specific therapy selected (including 
specific oral anticoagulant agents) in 132 (52.6%) 
patients. There was a moderate level of agreement 
between prescribers and CARATV2.0 regarding the 
use of anticoagulants versus other therapy (kappa 
= 0.275, p < 0.001). 
However, at discharge, prescribers did not 
follow the specific therapy recommendations of 
CARATV2.0 in 119 cases (Supplemental Table 2 
— see journal website). Most common reasons 
given were (a) desire to continue existing therapy, i.e. 
continue pre-admission therapy, (b) practical mana-
gement issues (e.g. “NOACs better/easier to man-
age/no need for monitoring”) and (c) perceived is-
www.cardiologyjournal.org 179
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sues of medication safety associated with potential 
risk of bleeding (fall risk, old age, dementia) (Fig. 2). 
In contrast, the benefit of treatment (reduction in 
stroke risk) and specific bleeding events (history 
of gastrointestinal bleeding) were among the least 
common reasons for not adhering to CARATV2.0’s 
recommendations.
Post hoc analysis: Consideration  
of NOACs as first-line therapy 
In the post hoc analysis, patients who were 
identified as unsuitable for any oral anticoagulant 
in the trial scenario also remained ineligible for 
any oral anticoagulant. Among those who were 
eligible for oral anticoagulants, 119 (47.4%) 
patients were recommended any of the NOACs 
(dabigatran, rivaroxaban or apixaban); 50 (19.9%) 
were recommended either rivaroxaban or 
apixaban; 29 (11.6%) apixaban only; 3 (1.2%) 
either dabigatran or rivaroxaban; and 1 (0.4%) 
either dabigatran or apixaban. Only 21 (12.6%) 
patients were recommended warfarin, 17 due to 
severe renal impairment (creatinine clearance 
< 25 min/1.73 m2) and 4 due to hepatic impairment. 
When examining the distribution of therapy, 
CARATV2.0’s recommendations in the trial 
scenario were better aligned with the treatment 
prescribed to patients at discharge in 132 (52.6%) 
patients, while CARATV2.0 recommendations in 
the post hoc analysis (NOACs as first-line therapy) 
only aligned with treatment prescribed to patients 
at discharge in 98 39.0% patients (p = 0.002). 
Discussion
In this study, a novel decision support tool 
(CARATV2.0), which considers warfarin as first-
line therapy and NOACs as alternative treatment 
options, was pilot-tested in a tertiary hospital. Re-
sults showed that CARATV2.0 assisted treatment 
selection and optimised the use of antithrombotic 
therapy in this patient population. More impor-
tantly, CARATV2.0 significantly increased the use 
of anticoagulants (warfarin and NOACs) in patients 
identified as eligible for oral anticoagulant therapy 
by this decision support tool. Moreover, since the 
average age of the patient population in this study 
was older than that of the general population of 
patients with AF [22], antithrombotic use in the 
general population may be further increased by 
the application of CARATV2.0. Because both 
national and international guidelines indicate the 
superiority of anticoagulants over antiplatelets for 
stroke prevention in patients with AF, the ability of 
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Table 2. Predictors of antithrombotic therapy choice.
Likelihood of receiving antiplatelets 
over anticoagulants†
Univariate  
analysis
Odds ratio (95%CI)
P Multivariate logistic 
regression
Odds ratio (95% CI)*
P
High risk of fall (previous frequent falls):
Yes 3.77 (1.93–7.37) < 0.001 2.25 (1.01–5.01) 0.04
No (Reference) 1
Prior history of intracranial bleeding:
Yes 3.45 (1.74–6.85) < 0.001 – –
No (Reference) 1
Cognitive impairment:
Yes 3.15 (1.30–7.64) 0.01 – –
No (Reference) 1
Bleeding risk‡:
Low bleeding risk 0.11 (0.04–0.30) < 0.001 0.20 (0.07–0.60) 0.004
Intermediate bleeding risk 0.16 (0.07–0.37) < 0.001 0.21 (0.08–0.51) 0.001
High bleeding risk (Reference) 1
Higher number of total medications:
Yes 1.11 (1.02–1.20) 0.02 – –
No (Reference) 1
*Cox & Snell R2 = 0.12, Nagelkerke R2 = 0.18, 80.8% correctly predicted
Likelihood of receiving warfarin  
over NOACs§
Univariate  
analysis
Odds ratio (95% CI)
P Multivariate logistic 
regression
Odds ratio (95%CI)**
P
Systolic blood pressure > 160 mm Hg:
Yes 0.23 (0.06–0.87) 0.03 0.18 (0.04–0.92) 0.04
No (Reference) 1
Chronic kidney disease:
Yes 3.25 (1.25–8.47) 0.02 3.96 (1.25–12.51) 0.02
No (Reference) 1
Prior GI bleeding/ulcer:
Yes 0.41 (0.19–0.91) 0.03 0.29 (0.09–0.94) 0.04
No (Reference) 1
Patients admitted to departments$:
General medicine department 3.00 (1.18–7.61) 0.02 4.67 (1.52–14.39) 0.01
Cardiology department 3.00 (1.21–7.43) 0.02 3.80 (1.26–11.47) 0.02
Aged care department 4.75 (1.54–14.58) 0.006 5.81 (1.42–23.81) 0.02
Neurology department (Reference) 1
**Cox & Snell R2 = 0.20, Nagelkerke R2 = 0.27, 71.2% correctly predicted
†Antiplatelets (including aspirin + clopidogrol, aspirin + dipyramidole, aspirin, clopidogrol) anticoagulants include warfarin and non-vitamin K 
antagonist oral anticoagulants (NOACs)
‡As assessed by HEMORR2HAGES  
§Including dabigatran or rivaroxaban or apixaban
$Patients admitted to the department
High risk of fall: previous frequent falls or high risk of fall as documented in clinical notes
Prior intracranial haemorrhage: all type of haemorrhagic stroke and subdural or subarachnoid haemorrhage
Cognitive impairment: all types of dementia and other cognitive impairment as documented in clinical notes
Chronic kidney disease: all types of chronic renal impairment as documented in clinical notes
Prior gastrointestinal bleeding/ulcer: all types of gastrointestinal bleeding and ulcer as documented in clinical notes
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Figure 2. Main reasons for not taking CARATV2.0’s recommendations; OAC — oral anticoagulants; GP — general 
practitioner.
Figure 1. Changes to antithrombotic therapy over the course of the study; NOACs — dabigatran, rivaroxaban or apixaban.
CARATV2.0 to improve the use of anticoagulants 
has a valuable role in clinical practice. 
Among factors affecting the selection of 
antithrombotics, bleeding risk and fall risk were 
the major barriers to prescribing anticoagulants 
[23]. The perceived association between a high 
risk of falls and ICH may have driven prescribers 
to avoid prescribing oral anticoagulants in those 
patients with a high fall risk [24]. However, 
a patient would need to fall about 300 times per 
year before their risk of ICH exceeds the benefits 
of using anticoagulation [25]. Moreover, there 
is no significant difference in the risk of ICH 
between therapy with NOACs such as apixaban and 
therapy with antiplatelets [26]. Therefore, for most 
patients, fall risk should not be a major barrier to 
prescribing an anticoagulant. 
In contrast, prescribers’ preference for pre-
scribing warfarin to patients with chronic kidney 
disease is understandable, as studies have shown 
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that NOACs should be used with caution in patients 
with renal impairment, and are contraindicated 
in patients with severe renal impairment [1]. Intere- 
stingly, compared with admission to the other 
departments, patients admitted to the neurology 
department were more likely to be prescribed 
NOACs than prescribed warfarin. Possibly, 
neurologists have a different approach to selecting 
an antithrombotic therapy that is more aligned with 
international guidelines [27].
The treatment received by patients at discharge 
better aligned with CARATV2.0 recommendations 
when warfarin was considered as the first-line 
therapy, which suggests that most prescribers 
are still cautious of using NOACs as the first-
line therapy. Although the majority of prescribers 
agreed with CARATV2.0 recommendations to 
prescribe anticoagulants, some cited reasons for not 
taking CARATV2.0 recommendations for specific 
antithrombotic agents. The desire to continue 
therapy, and issues of practical management and 
medication safety were cited as the major reasons 
for not accepting CARATV2.0 recommendations. 
Among these reasons, the desire to continue pre-
admission therapy was commonly cited, which 
indicates that prescribers are reluctant to change 
therapy once initiated [28]. Although important 
issues of medication safety (fall risk, advanced age 
and dementia) and bleeding risk are considered 
by CARATV2.0 when making recommendations, 
some prescribers still cited these reasons for not 
prescribing anticoagulants. Thus, prescribers 
apparently perceived some factors as more risky than 
the evidence suggests. The concerns about issues of 
practical management and medication safety indicate 
that hospital prescribers are still worried about the 
long-term management of antithrombotic therapy by 
general practitioners and about the risk of adverse 
events. However, studies have shown that general 
practitioners are more focused on the benefits of 
antithrombotic therapy for patients [29].
In the post hoc analysis, it was also shown that 
CARATV2.0 can be adapted to an international set-
ting, where there may be differences in guideline 
recommendations (in terms of whether NOACs 
or warfarin are used first-line). The assessment 
process of CARATV2.0 may be adjusted in terms of 
which agent is advocated as the first-line therapy. 
Therefore, for international users, CARATV2.0 can 
be customised to align with the local guidelines of 
each country. The tool’s adaptability to other set-
tings may be important, not only in terms of what 
the local guidelines advocate, but also in terms 
of cost implications. In Australia, both warfarin 
and NOACs are cost-subsidised by the Australian 
government [30], whereas in other countries the 
high-cost of NOACs may be borne by the patients, 
and these cost implications may impact treatment 
preferences. 
Limitations of the study
In consideration of these findings, some limi-
tations of the study need to be acknowledged. 
Although CARATV2.0 was developed with the 
latest evidence and treatment options available at 
the time, its algorithm may need to change as new 
evidence and therapies arise. Furthermore, one 
of the current limitations of CARATV2.0 is that it 
does not make recommendations around the use of 
combination therapy (e.g., an anticoagulant plus an 
antiplatelet) in patients with multiple indications. 
Future study would do well to consider how this 
can be addressed. In addition, this study focused 
on patients with AF who were admitted to one hos-
pital. Therefore, the results might not generalize 
to a broader AF population. Due to the lack of 
a control group in this study, it is uncertain whether 
changes to therapy might have occurred without 
the intervention of CARATV2.0. Finally, this pilot 
study did not explore the clinical outcomes of 
patients. Clinical trials in a broader patient popula-
tion, involving comparisons to a control group, and 
with long-term follow-up, are needed to further 
evaluate the efficacy of this decision support tool.
Conclusions
In this study, CARATV2.0 successfully in-
creased the use of anticoagulants in patients with 
AF and, when risk versus benefit profiles were 
taken into account, it demonstrated potential in the 
selection of an appropriate antithrombotic therapy. 
In the decision-making process of antithrombotic 
therapy, there are inter-speciality differences in 
therapy selection. In addition, prescribers were 
reluctant to change therapy once initiated citing 
perceived factors such as fall risk and age as being 
more risky than the evidence would suggest.
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